JLB & Associates Inc. grew its holdings in shares of Icon Plc (NASDAQ:ICLR) by 18.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 33,549 shares of the medical research company’s stock after acquiring an additional 5,274 shares during the quarter. JLB & Associates Inc. owned about 0.06% of Icon worth $6,410,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the company. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its holdings in shares of Icon by 54.2% in the second quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,020 shares of the medical research company’s stock valued at $340,000 after acquiring an additional 710 shares in the last quarter. Handelsbanken Fonder AB bought a new stake in shares of Icon in the 2nd quarter worth approximately $2,123,000. Sigma Planning Corp acquired a new stake in Icon during the second quarter valued at approximately $273,000. Vident Investment Advisory LLC bought a new stake in Icon during the second quarter worth approximately $424,000. Finally, Advisors Asset Management Inc. grew its position in Icon by 9.4% in the first quarter. Advisors Asset Management Inc. now owns 17,037 shares of the medical research company’s stock worth $2,317,000 after buying an additional 1,461 shares during the last quarter. 83.74% of the stock is owned by institutional investors.
A number of equities research analysts have recently commented on the company. BidaskClub downgraded Icon from a “buy” rating to a “hold” rating in a research report on Friday. Mizuho upped their target price on Icon from $170.00 to $195.00 and gave the company a “buy” rating in a report on Monday, July 27th. They noted that the move was a valuation call. BofA Securities cut Icon from a “buy” rating to a “neutral” rating in a research note on Friday, July 24th. Credit Suisse Group boosted their price objective on Icon from $181.00 to $205.00 and gave the stock an “outperform” rating in a report on Thursday, July 23rd. Finally, Jefferies Financial Group raised their target price on shares of Icon from $184.00 to $220.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Ten analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $178.45.
Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, July 22nd. The medical research company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.10 by $0.10. Icon had a net margin of 12.03% and a return on equity of 22.21%. The business had revenue of $620.23 million for the quarter, compared to analysts’ expectations of $594.31 million. On average, sell-side analysts anticipate that Icon Plc will post 6.26 earnings per share for the current year.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.